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inflammatory agents in prevention of restenosis after percutaneous 
transluminal coronary angioplasty did not result in favorable out-
come (I). The unfavorable outcome in trial of corticosteroids in 
prevention of restenosis is a reflection of a shotgun approach to a 
complex problem. In this context, it is important to remember that 
antiplatelet drugs, beta-adrenergic antagonists, calcium channel 
antagonists and cholesterol-lowering agents all have been shown to 
decrease or prevent atherosclerosis in experimental animals, but 
these therapies have had only modest and variable effect in man. 
Antiplatelet agents which decrease mortality in acute myocardial 
ischemia are not very effective in patients who have undergone 
coronary angioplasty. 
We noted Chaldakov's interest in colchicine and griseofulvin as 
potential therapy for mUltiple manifestation of ischemic heart dis-
ease. Indeed the role of colchicine is presently being investigated in 
prevention of restenosis of coronary arteries after angioplasty. 
However, we feel a cautious approach to use of generic anti-
inflammatory agents is warranted, because each ischemic heart 
disease syndrome may have its own peculiarities relative to its 
genesis. For example, initial thrombosis in atherosclerotic coronary 
arteries may be a platelet-dependent phenomenon, whereas re-
thrombosis after coronary thrombolysis may be due to predominant 
deposition of fibrin. 
In this era of cellular and molecular cardiology, attempts need to 
be made to define precise cellular steps in the evolution of disease 
process prior to institution of shotgun therapy. Until we understand 
the complex cellular interactions and the pathogenesis of tissue 
injury, a multi pronged therapy may need to be used. 
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Endothelial Cells and Not Smooth Muscle 
Cells Are Affected During a Photodynamic 
Therapy of Atherosclerotic Plaques 
Dartsch et al. (I) question why atherosclerotic plaque smooth 
muscle cells are in vitro more sensitive to hematoporphyrin-
derivative photodynamic therapy than synthetic phenotype normal 
smooth muscle cells although the former manifest a lower prolifer-
ative activity than the latter. The easiest and most probably the 
correct explanation is that these cells are not identical as it is 
assumed conventionally. It must not be forgotten that a concept of 
the medial smooth muscle cell behaving as multi potential mesen-
chyme is based on the studies carried out in vitro and, if in vivo, 
then only on nonhuman material (2). In other words, it has never 
been proved in human atherosclerosis that synthetic phenotype 
smooth muscle cells of a plaque derive from fully differentiated 
medial smooth muscle cells. 
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Recently, undifferentiated vascular endothelial cells or postem-
bryonic undifferentiated mesenchymal cells (3) were described in 
coronary allograft atherosclerosis (4). As far as I know this is the 
first evidence that the same cells may form capillary sprouts in the 
periarterial space, infiltrate the arterial wall and participate in a 
formation of intimal thickening. This observation is in keeping with 
the fact that scientists had presumed since long ago that the vasa 
va sorum were involved in a reaction of the arterial wall to injury but 
had not realized how the vasa vasorum could contribute to intimal 
thickening (5). Only recently, Diaz-Florez and Dominguez (6) and 
Sarkisov et al. (7) proposed that intimal thickening fibroblastic cells 
derive from capillary cells. Their communications inspired me to 
review the older literature concerning this subject. It came as a 
surprise to me to learn that Winternitz et al. (8) almost succeeded in 
defining a histogenesis of the atherosclerotic plaque in 1938(!). 
These authors visualized round clear cells surrounded by collag-
enous fibers into the cytoplasm of which red blood cells were 
penetrating (their Fig. 76). These cells are undifferentiated capillary 
endothelial cells which may differentiate into smooth muscle cells 
and fibroblasts or redifferentiate into flat vascular endothelial cells. 
A great many undergo necrosis leaving red blood cells behind them 
among collagenous fibers (their Fig. 89). When accentuated, this 
process may lead to arterial dissection (their Fig. 96). As far as this 
pathologic phenomenon is concerned, the observation ofWinternitz 
et al. (8) also fell into oblivion (9). These authors did not realize, 
however, the relation between the differentiated and undifferenti-
ated endothelial cells and between the undifferentiated endothelial 
and smooth muscle cells, considering the former to be an inflamma-
tory mononuclear cell phagocytizing erythrocytes (p 114). This fact 
does not diminish their merits because Winternitz et al. (8) ulti-
mately drew a correct conclusion from their observations: "The 
response to injury is mediated through the capillary bed and is 
manifested by two more or less distinct and variably proportioned 
reactions: exudation and proliferation .... Proliferation consists of 
new formation of blood vessels and connective tissue elements, 
including fibroblasts and many varieties of mononuclear cells." 
Undifferentiated capillary endothelial cells migrate during angio-
genesis (10) and therefore possess contractile myofilaments. Conse-
quently, they may be perceived as myofibroblasts or mistaken for 
synthetic phenotype smooth muscle cells. 
This information helps us to understand why atherosclerotic 
plaque cells are more sensitive to hematoporphyrin derivative 
photodynamic therapy than medial smooth muscle cells. Vascular 
endothelial cells manifest a particular affinity for photosensitizers 
such as porphyrins in both experimental (II) or clinical (12) situa-
tions. 
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Atrial Natriuretic Factor 
Edwards and colleagues' evidence (1) further advances our under-
standing of atrial natriuretic factor by identifying this polypeptide 
(or group of polypeptides) (2) in the ventricle and its relation to 
ventricular dilation. Yet, the role of transmural pressure (rather than 
"filling" pressure) is not as clear here as it is in the atrium, where 
despite very high intracavitary pressure, the average transmural 
pressure can be effectively small to zero-as in cardiac tamponade 
and constriction (3)-the expression of atrial natriuretic factor is 
drastically reduced (2). The authors established their evidence for 
ventricular production of atrial natriuretic factor as being indepen-
dent of static chamber dilation. But atrial natriuretic factor produc-
tion is minimized in cardiac tamponade and constriction because the 
atria cannot dynamically dilate and filling is greatly reduced (atrial 
and wedge pressures despite their high levels are thus not really 
"filling" pressures) (3). It would be of considerable interest to know 
if the authors have evidence on ventricular atrial natriuretic factor 
production during pericardial compression of a diseased ventricle. 
That is, is the stimulus stretch, as in the atrium, rather than dilation? 
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Reply 
Although atrial natriuretic factor is not present in the normal 
ventricle, we have observed its expression in ventricular tissue from 
patients with both restrictive and dilated disorders. 
In regard to the role of transmural pressure, it is important to 
make a distinction between release of atrial natriuretic factor and 
induction of atrial natriuretic factor gene expression. As we have 
previously reported (1), increased atrial transmural pressure results 
in an acute increase in plasma atrial natriuretic factor. This obser-
vation demonstrates release of atrial natriuretic factor and does not 
evaluate peptide synthesis. We have previously observed that in 
congestive heart failure, there exists an inverse relation between 
atrial atrial natriuretic factor content and circulating levels of the 
peptide (2). To our knowledge, no study has examined the relation 
between ventricular atrial natriuretic factor tissue content and 
circulating levels in states in which the pericardium compresses a 
diseased ventricle. When the existence of ventricular atrial natri-
uretic factor was first reported in the dilated human heart (3), we 
observed a concentration gradient, such that the suberidocardial 
tissue contained more atrial natriuretic factor than did the subepi-
cardial regions of the ventricle. In evaluating the relation between 
ventricular atrial natriuretic factor content and wall stress, average 
transmural stress may not accurately reflect the situation. Ritman 
and colleagues (4) have demonstrated a transmural gradient in 
myocardial stress-strain relation. In diseased states the subendocar-
dial region of the left ventricle is the area richest in ventricular atrial 
natriuretic factor and is also the atea of highest myocardial stress. 
This observation and our previous observation that ventricular atrial 
natriuretic factor appears to occur in states in which left ventricular 
end-diastolic pressure is elevated, demonstrate interesting arid im-
portant correlations; however, further work will be required to 
ultimately demonstrate the mechanisms responsible for these rela-
tions. 
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